Xenon Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
Current Price
$54.12
-1.02%Profile
Valuation (TTM)
Market Cap$4.50B
P/E-11.75
EV—
P/B7.74
Shares Out83.19M
P/Sales—
Revenue$0.00
EV/EBITDA—
Xenon Pharmaceuticals Inc (XENE) Stock News
XENE Stock News & Headlines
Latest stock news and headlines for Xenon Pharmaceuticals Inc (XENE). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $54.12. Market cap: $4.50B. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to XENE from financial news sources, helping investors stay current on events that may impact Xenon Pharmaceuticals Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Xenon Pharmaceuticals Inc (XENE).